1. 要旨
2. 分類学と市場定義を含む業界紹介
3. 市場動向と成功要因（マクロ経済要因、市場ダイナミクス、最近の業界動向など
4. 歴史分析と将来予測を含む世界市場の需要分析2019年～2023年および予測2024年～2034年
5. 世界市場の分析 2019～2023年および2024～2034年予測
5.1. SCIDの種類
5.2. 治療タイプ
5.3. ベクターの種類
5.4. 患者の年齢層
5.5. 価格設定モデル
5.6. 開発段階
5.7. エンドユーザー
6. SCIDタイプ別の世界市場分析2019〜2023年および予測2024〜2034年
6.1. X連鎖性SCID
6.2. ADA-SCID型
6.3. その他のSCID
7. 世界市場分析2019～2023年および予測2024～2034年：治療タイプ別
7.1. 遺伝子置換療法
7.2. 遺伝子編集療法
7.3. 幹細胞遺伝子治療
8. ベクタータイプ別の世界市場分析2019〜2023年および予測2024〜2034年
8.1. ウイルスベクター
8.2. 非ウイルス性ベクター
9. 世界市場分析2019～2023年および予測2024～2034年：患者年齢層別
9.1. 小児患者
9.2. 成人患者
10. 世界市場分析2019～2023年および予測2024～2034年：価格モデル別
10.1. 単回投与治療
10.2. 多剤投与治療
11. 世界市場分析2019～2023年および予測2024～2034年：開発段階別
11.1. 前臨床
11.2. 臨床試験
11.3. 商業化
12. 世界市場分析2019～2023年および予測2024～2034年：エンドユーザー別
12.1. 病院
12.2. 専門クリニック
12.3. 研究機関
13.
世界市場分析2019～2023年および予測2024～2034年、地域別
13.1.
北米
13.2.中南アメリカ
13.3.西ヨーロッパ
13.4.東欧
13.5.東アジア
13.6.南アジア・太平洋
13.7.MEA
14.北米の主要セグメント・国別売上高分析 2019～2023年および予測 2024～2034年
15.中南アメリカ 売上高分析 2019～2023年および2024～2034年予測：主要セグメント・国別
16.西欧売上高分析 2019～2023年および2024～2034年予測：主要セグメント・国別
17.東欧売上高分析 2019～2023年および2024～2034年予測：主要セグメント・国別
18.東アジアの売上高分析 2019～2023年および2024～2034年予測：主要セグメント・国別
19.南アジア・太平洋地域の売上高分析 2019～2023年および2024～2034年予測：主要セグメント・国別
20. MEA売上高分析 2019～2023年および2024～2034年予測：主要セグメント別、国別
21. 世界30ヵ国におけるSCIDタイプ、治療法タイプ、ベクタータイプ、患者年齢層、価格設定モデル、開発段階、エンドユーザー別の2024～2034年売上高予測
22. 市場構造分析、主要プレイヤー別企業シェア分析、競争ダッシュボードを含む競争展望
23. 企業プロフィール
23.2. OSR and Telethon
23.3. Jasper Therapeutics, Inc.
23.4. Graphite Bio, Inc.
23.5. Mustang Bio Inc
23.6. University of California San Francisco
23.7. Genethon SA
23.8. Boston Children’s Hospital
23.9. Shenzhen Geno-Immune Medical Institute
23.10. University College London
23.11. University of California Los Angeles
23.12. The National Institute of Allergy and Infectious Diseases
Gene Therapy for SCID Market - Scope of ReportA recent study by Fact.MR on the gene therapy for scid market offers a 10-year forecast for 2024 to 2034. The study analyzes crucial trends that are currently determining the growth of the market. This report explicates on vital dynamics, such as the drivers, restraints, and opportunities for key market players along with key stakeholders as well as emerging players associated with offering gene therapy for scid.
The study also provides the dynamics responsible for influencing the future status of the gene therapy for scid market over the forecast period. A detailed assessment of value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report.
A list of prominent companies operating in the gene therapy for scid market, along with their product portfolios, key strategies and SWOT analysis, enhances the reliability of this comprehensive research study.
Report Summary
The study offers comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales of gene therapy for scid across the globe.
A comprehensive estimate on the market has been provided through an optimistic as well as a conservative scenario, taking into account the sales of gene therapy for scid during the forecast period. Price point comparison by region with global average price is also considered in the study.
Analysis on Market Size Evaluation
The market has been analyzed for each segment in terms of value (US$ Mn).
Estimates at global and regional levels for gene therapy for scid are available in terms of “US$ Mn” for value. A Y-o-Y growth contrast on prominent market segments, along with market attractiveness evaluation, has been incorporated in the report. Furthermore, absolute dollar opportunity analysis of all the segments adds prominence to the report.
Absolute dollar opportunity plays a crucial role in assessing the level of opportunity that a manufacturer/distributor can look to achieve, along with identifying potential resources, considering the sales and distribution perspective in the global gene therapy for scid market.
Inspected Assessment on Regional Segments
Key sections have been elaborated in the report, which have helped deliver projections on regional markets. These chapters include regional macros (political, economic, and business environment outlook), which are expected to have a momentous influence on the growth of the gene therapy for scid market during the forecast period.
Country-specific valuation on demand for gene therapy for scid has been offered for each region, along with market scope estimates and forecasts, price index, and impact analysis of the dynamics of prominence in regions and countries. For all regional markets, Y-o-Y growth estimates have also been incorporated in the report.
Detailed breakup in terms of value & volume for emerging countries has also been included in the report.
In-depth Analysis on Competition
The report sheds light on leading manufacturers of gene therapy for scid, along with their detailed profiles. Essential and up-to-date data related to market performers who are principally engaged in offering gene therapy for scid has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits report readers to take preemptive steps in advancing their businesses.
Company profiles have been included in the report, which include essentials such as product portfolios and key strategies, along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through a matrix for all the prominent players, thus providing readers with actionable insights, which helps in thoughtfully presenting the market status, and predicting the competition level in the gene therapy for scid domain.
1. Executive Summary
2. Industry Introduction, including Taxonomy and Market Definition
3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments
4. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections
5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034
5.1. Type of SCID
5.2. Therapy Type
5.3. Vector Type
5.4. Patient Age Group
5.5. Pricing Model
5.6. Phase of Development
5.7. End-User
6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Type of SCID
6.1. X-Linked SCID
6.2. ADA-SCID
6.3. Other SCID Types
7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Therapy Type
7.1. Gene Replacement Therapy
7.2. Gene Editing Therapy
7.3. Stem Cell Gene Therapy
8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Vector Type
8.1. Viral Vectors
8.2. Non-Viral Vectors
9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Patient Age Group
9.1. Pediatric Patients
9.2. Adult Patients
10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Pricing Model
10.1. Single-dose treatments
10.2. Multi-dose treatments
11. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Phase of Development
11.1. Preclinical
11.2. Clinical Trials
11.3. Commercialized
12. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By End-User
12.1. Hospitals
12.2. Specialty Clinics
12.3. Research Institutions
13. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
13.1. North America
13.2. Latin America
13.3. Western Europe
13.4. Eastern Europe
13.5. East Asia
13.6. South Asia & Pacific
13.7. MEA
14. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
15. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
16. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
17. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
18. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
19. South Asia & Pacific Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
20. MEA Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
21. Sales Forecast 2024 to 2034 by Type of SCID, Therapy Type, Vector Type, Patient Age Group, Pricing Model, Phase of Development, and End-User for 30 Countries
22. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard
23. Company Profile
23.1. Orchard Therapeutics plc.
23.2. OSR and Telethon
23.3. Jasper Therapeutics, Inc.
23.4. Graphite Bio, Inc.
23.5. Mustang Bio Inc
23.6. University of California San Francisco
23.7. Genethon SA
23.8. Boston Children's Hospital
23.9. Shenzhen Geno-Immune Medical Institute
23.10. University College London
23.11. University of California Los Angeles
23.12. The National Institute of Allergy and Infectious Diseases
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
